Metformin to Augment Strength Training Effective Response in Seniors (MASTERS)

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

EARLY_PHASE1

Total Enrollment

109 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-01-14

Study Completion Date

2018-06-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine whether a commonly prescribed drug, metformin, can enhance the benefits seen during resistance exercise such as increased muscle mass and strength.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Short-Term Metformin Use in Young, Healthy Adults: Impacts on Exercise Capacity

NCT06638671

Exercise Capacity Metformin

RECRUITING PHASE4

Exercise Dose and Metformin for Vascular Health in Metabolic Syndrome

NCT03355469

Metabolic Syndrome

COMPLETED PHASE2/PHASE3

Mechanisms by Which Strength Training Ameliorates the Metabolic Syndrome

NCT00727779

Metabolic Syndrome

COMPLETED NA

Diet and Exercise Interventions to Increase Muscle Strength and Function

NCT02850562

Obesity Sarcopenia Metabolic Syndrome X

COMPLETED NA

The Influence of Different Dietary Status on the Acute Responses to Exercise

NCT02870075

Adipose Tissue Gene Expression

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Muscle mass and strength are critical determinants not only of a person's quality of life and functional independence, but also metabolic health, as muscle is the organ primarily responsible for insulin-mediated glucose uptake. The elderly suffer obligatory losses of muscle mass and strength, exacerbated by illness and physical inactivity. Progressive resistance exercise training (PRT) is the most effective intervention identified to improve muscular strength, and combat the muscle atrophy of aging (sarcopenia); however, overall the muscle response to PRT is blunted in the elderly and variability of response increased, with some individuals actually losing muscle mass. The Bamman and Peterson labs have independently been studying the molecular and cellular mechanisms underlying the "non-responder" phenotype, with the goal of identifying novel intervention strategies to promote mass and strength gains to improve function. We hypothesize that the abundance of anti-inflammatory, alternatively activated M2 macrophages in muscle predicts response to PRT in the elderly; those with the highest number of M2 macrophages and lowest inflammatory gene expression prior to the start of training gained the most mass. Further, we determined that metformin treatment increased M2 macrophage abundance, and decreased inflammatory cytokine gene expression. These provocative findings have led us to our central hypothesis that adjuvant metformin may improve the responses to PRT in the elderly by altering the muscle tissue inflammatory environment, thereby enhancing mechanisms that drive PRT-induced myofiber hypertrophy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Aging

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Metformin

Participants will be randomized to receive Metformin (1700 mg/day) for a period of 16 weeks; 2 weeks of Metformin only followed by 14 weeks of continued Metformin use in combination with progressive resistance training.

Group Type EXPERIMENTAL

Progressive Resistance Training

Intervention Type BEHAVIORAL

Participants will complete 14 weeks (42 sessions, 3x/week) of progressive resistance training which will consist of 8 constant load movements to train all major muscle groups bilaterally.

Metformin

Intervention Type DRUG

Participants will be randomized to receive metformin in conjunction with their strength training program.

Placebo, Sugar Pill

Participants will be randomized to receive placebo sugar pills (1700 mg/day) for a period of 16 weeks; 2 weeks of placebo only followed by 14 weeks of continued placebo use in combination with progressive resistance training. Placebos will be almost identical to the Metformin medication.

Group Type PLACEBO_COMPARATOR

Progressive Resistance Training

Intervention Type BEHAVIORAL

Participants will complete 14 weeks (42 sessions, 3x/week) of progressive resistance training which will consist of 8 constant load movements to train all major muscle groups bilaterally.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Progressive Resistance Training

Participants will complete 14 weeks (42 sessions, 3x/week) of progressive resistance training which will consist of 8 constant load movements to train all major muscle groups bilaterally.

Intervention Type BEHAVIORAL

Metformin

Participants will be randomized to receive metformin in conjunction with their strength training program.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Strength Training Glucophage XR

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* ≥65 years of age.
* Independently mobile with a SPPB score 3-12.
* Access to transportation.
* Capable of providing informed consent (cognitively intact).

Exclusion Criteria

* Obesity (BMI\>30)
* Serum creatinine \>1.4 because of risk of lactic acidosis with metformin.
* History of regular resistance training within the past year.
* History (or ECG evidence) of previous myocardial infarction, history of congestive heart failure.
* Current angina pectoris or symptoms of myocardial ischemia or congestive heart failure.
* Chronic aspirin or NSAID use (unless it can be safely stopped prior to the biopsies), and any other use of an anticoagulant (e.g., Coumadin) or history of bleeding.
* History of alcoholism or liver disease.
* History of hypo- or hyper-coagulation disorders including subjects taking Coumadin.
* Any end-stage disease and/or a life expectancy less than one year.
* Neurological, musculoskeletal, or other disorder that would preclude them from completing resistance training and all performance tests.
* Uncontrolled hypertension.
* Diabetes mellitus as demonstrated with- HgbA1C\>6.5, or fasting glu\>126 mg/dl.
* Any other medical condition that would interfere with testing or increase one's risk of complications during exercise, as judged by the study physicians.
* Any other condition or events considered exclusionary by the PI and/or physician, such as non-compliance.
* Lidocaine allergy (1% lidocaine is the local anesthetic used during the muscle biopsy procedure).

Minimum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes